Other metabolic agents (local RU classification)
ATC code: V03AX-MEXIDOL (Ethylmethylhydroxypyridine succinate (local code))
The manufacturer claims antioxidant, antihypoxic, and membrane-stabilizing effects via lipid bilayer stabilization and activation of succinate dehydrogenase. The molecule is not mentioned in international sources, and independent mechanism-of-action studies have not been published.
Not recommended
The term 'dyscirculatory encephalopathy' is absent from international neurology and from ICD-11. Mexidol for cognitive impairment and chronic cerebral ischemia is not mentioned in AAN or ESO recommendations. Evidence-based management of vascular cognitive dysfunction relies on vascular risk factor control, physical activity, and cognitive training.
Not recommended
For the treatment of anxiety disorders, Mexidol is not mentioned in international clinical guidelines (APA, NICE). Evidence-based options include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine), and cognitive behavioral therapy.
Not recommended
In international guidelines for acute ischemic stroke management (AHA/ASA 2019, ESO 2021), Mexidol and other 'neuroprotectors' are not mentioned. Proven acute therapies include systemic thrombolysis with tissue plasminogen activator within 4.5 hours of symptom onset and mechanical thrombectomy within 6–24 hours in selected patients.
Not recommended
Neuroprotective therapy for TIA is not used in international clinical guidelines. TIA management relies on early antiplatelet (or anticoagulant) therapy, statin therapy, modification of risk factors, and workup for an embolic source.
Contraindicated in pregnancy per manufacturer label. International sources provide no recommendations.